Physician profile
Robin Ray
NPI 1306006226
$7,099.91
in general payments reported to CMS, 2019-2025
12 companies · $364 in 2025
The $364 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $961 · 2020: $758 · 2021: $1,615 · 2022: $2,711 · 2023: $392 · 2024: $298 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,054.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $5,461.47 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $808.96 | 2021-2025 | Eylea, Eylea Hd |
| Genentech USA, INC. | $494.81 | 2019-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $70.87 | 2023 | Syfovre |
| Eyepoint US, INC. | $66.49 | 2021-2023 | |
| Harrow Eye, LLC | $56.09 | 2025 | |
| Novartis Pharmaceuticals Corporation | $35.38 | 2020-2021 | |
| Abbvie INC. | $23.50 | 2024 | |
| Alimera Sciences, INC. | $23.20 | 2023 | Yutiq |
| Ani Pharmaceuticals, INC. | $21.49 | 2025 | Yutiq |
| Coherus Oncology, INC. | $19.84 | 2022 | |
| Sun Pharmaceutical Industries INC. | $17.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$190,471.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.